NO931580D0 - Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor - Google Patents

Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor

Info

Publication number: NO931580D0
Authority: NO; Norway
Prior art keywords: tnf; antibody; xanthine; range; xanthine derivative
Prior art date: 1990-11-01

Application number

NO931580A

Other languages

English (en)

Norwegian (no)

Inventor

Hiristo Anagnostopulos

Ulrich Gebert

Heinz Hanel

Michael Limbert

Mark William Bodmer

Gerald Anthony Higgs

Original Assignee

Celltech Ltd

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-01

Filing date

1993-04-30

Publication date

1993-04-30

1993-04-30 Application filed by Celltech Ltd, Hoechst Ag filed Critical Celltech Ltd

1993-04-30 Publication of NO931580D0 publication Critical patent/NO931580D0/no

Links

239000012634 fragment Substances 0.000 title abstract 4
238000002360 preparation method Methods 0.000 title abstract 2
238000002648 combination therapy Methods 0.000 title 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 5
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 abstract 3
206010040070 Septic Shock Diseases 0.000 abstract 3
206010014824 Endotoxic shock Diseases 0.000 abstract 1
NWXULHNEYYFVMF-UHFFFAOYSA-N albifylline Chemical compound O=C1N(CCCCC(C)(C)O)C(=O)N(C)C2=C1NC=N2 NWXULHNEYYFVMF-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000004957 immunoregulator effect Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 1
229960001476 pentoxifylline Drugs 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000036303 septic shock Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO931580A 1990-11-01 1993-04-30 Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor NO931580D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB909023783A GB9023783D0 (en)	1990-11-01	1990-11-01	Pharmaceutical product
PCT/GB1991/001907 WO1992007585A1 (en)	1990-11-01	1991-10-30	The use of antibodies to tnf or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor

Publications (1)

Publication Number	Publication Date
NO931580D0 true NO931580D0 (no)	1993-04-30

Family

ID=10684716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO931580A NO931580D0 (no)	1990-11-01	1993-04-30	Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor

Country Status (15)

Country	Link
EP (1)	EP0564461B1 (de)
JP (1)	JP3468515B2 (de)
KR (1)	KR930701970A (de)
AT (1)	ATE146971T1 (de)
AU (1)	AU653180B2 (de)
CA (1)	CA2094154A1 (de)
DE (1)	DE69123984T2 (de)
DK (1)	DK0564461T3 (de)
ES (1)	ES2096662T3 (de)
GB (1)	GB9023783D0 (de)
GR (1)	GR3022210T3 (de)
HU (1)	HUT70267A (de)
NO (1)	NO931580D0 (de)
WO (1)	WO1992007585A1 (de)
ZA (1)	ZA918712B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9109645D0 (en) *	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1994008619A1 (en) *	1992-10-08	1994-04-28	The Kennedy Institute Of Rheumatology	Treatment of autoimmune and inflammatory disorders
US6770279B1 (en)	1992-10-08	2004-08-03	The Kennedy Institute Of Rheumatology	TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
DE69420137T2 (de)	1993-06-03	1999-12-23	Therapeutic Antibodies, Inc.	Herstellung von antikörperfragmenten
AU1090795A (en)	1993-11-12	1995-05-29	Cell Therapeutics, Inc.	Method for preventing tissue injury from hypoxia
DE4411660A1 (de) *	1994-04-05	1995-10-12	Hoechst Ag	Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DK0942740T3 (da) *	1996-12-06	2003-12-15	Amgen Inc	Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
EP1352656A3 (de) *	1996-12-06	2004-02-04	Amgen Inc.	Kombinationtherapie mit einem tnf-bindendem Protein zür behandlung von durch tnf verursachten Erkrangungen
US6294350B1 (en) *	1997-06-05	2001-09-25	Dalhousie University	Methods for treating fibroproliferative diseases
US6395273B1 (en) *	1998-06-10	2002-05-28	Promega Corporation	Prevention and treatment of inflammatory bowel disease

1990
- 1990-11-01 GB GB909023783A patent/GB9023783D0/en active Pending
1991
- 1991-10-30 DE DE69123984T patent/DE69123984T2/de not_active Expired - Fee Related
- 1991-10-30 WO PCT/GB1991/001907 patent/WO1992007585A1/en not_active Ceased
- 1991-10-30 HU HU9301093A patent/HUT70267A/hu unknown
- 1991-10-30 CA CA002094154A patent/CA2094154A1/en not_active Abandoned
- 1991-10-30 EP EP91918565A patent/EP0564461B1/de not_active Expired - Lifetime
- 1991-10-30 AT AT91918565T patent/ATE146971T1/de not_active IP Right Cessation
- 1991-10-30 AU AU87583/91A patent/AU653180B2/en not_active Ceased
- 1991-10-30 KR KR1019930701250A patent/KR930701970A/ko not_active Withdrawn
- 1991-10-30 ES ES91918565T patent/ES2096662T3/es not_active Expired - Lifetime
- 1991-10-30 DK DK91918565.2T patent/DK0564461T3/da active
- 1991-10-30 JP JP51773591A patent/JP3468515B2/ja not_active Expired - Lifetime
- 1991-11-01 ZA ZA918712A patent/ZA918712B/xx unknown
1993
- 1993-04-30 NO NO931580A patent/NO931580D0/no unknown
1997
- 1997-01-03 GR GR960403495T patent/GR3022210T3/el unknown

Also Published As

Publication number	Publication date
DE69123984D1 (de)	1997-02-13
HUT70267A (en)	1995-09-28
ES2096662T3 (es)	1997-03-16
GR3022210T3 (en)	1997-04-30
AU653180B2 (en)	1994-09-22
ATE146971T1 (de)	1997-01-15
JP3468515B2 (ja)	2003-11-17
GB9023783D0 (en)	1990-12-12
DE69123984T2 (de)	1997-05-22
CA2094154A1 (en)	1992-05-02
AU8758391A (en)	1992-05-26
ZA918712B (en)	1992-09-30
DK0564461T3 (da)	1997-01-20
KR930701970A (ko)	1993-09-08
HU9301093D0 (en)	1993-07-28
EP0564461B1 (de)	1997-01-02
WO1992007585A1 (en)	1992-05-14
EP0564461A1 (de)	1993-10-13
JPH06502629A (ja)	1994-03-24

Similar Documents

Publication	Publication Date	Title
DK0564461T3 (da)	1997-01-20	Anvendelse af antistoffer mod TNF eller fragmenter afledt deraf og xanthinderivater til kombinationsterapi samt præparater dertil
DE69724451D1 (de)	2003-10-02	Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
BR9710811A (pt)	1999-08-17	Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
NO20053862L (no)	2005-10-31	Aktiv immunisering for a danne antistoffer mot loselig A-beta
DK0751781T3 (da)	2004-08-09	Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
NO913211L (no)	1991-08-16	Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
IL103981A0 (en)	1993-05-13	Pharmaceutical compositions for treatment of multiple sclerosis
NO175042C (de)	1994-08-24
ATE415173T1 (de)	2008-12-15	Pan dr-bindeproteinen zur erhöhung der immunantwort
HU0102070D0 (en)	2001-07-30	Use of vascular endothelial cell growth factor (hvegf) antagonists
DE68927671D1 (de)	1997-02-27	Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
WO1998026747A3 (en)	1998-09-17	Superantigen based methods and compositions for treatment of diseases
NO914541L (no)	1992-05-22	Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner
WO1992012715A3 (en)	1992-09-03	The use of loperamide and related compounds for treatment of respiratory disease symptoms
DE68921979D1 (de)	1995-05-04	Antikörper für die antilymphozyten-antikörpertherapie.
DE60217107D1 (de)	2007-02-08	Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
EP0369816A3 (de)	1990-09-12	Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
WO1996020950A3 (en)	1996-09-12	Compositions and methods for treating rheumatoid arthritis
DE3371515D1 (en)	1987-06-19	Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
NO961423D0 (no)	1996-04-11	Oligopeptider avledet fra C-reaktive proteinfragmenter
SE8402199D0 (sv)	1984-04-19	Pharmazeutisches preparat enthaltend co-dergocrine und einen calcium-antagonisten
Plescia et al.	1961	Fractionation and immunological properties of a DNA-rich preparation from Brucella abortus.
RU2519196C2 (ru)	2014-06-10	Лекарственное средство для лечения патологического синдрома и способ лечения рассеянного склероза
NO970165L (no)	1997-03-14	Kortikotropin frigivningsfaktor-bindingsprotein inhibitorer og deres anvendelse
Roszkiewicz et al.	2018	Tocilizumab w leczeniu młodzieńczego idiopatycznego zapalenia stawów o początku uogólnionym–doświadczenia własne